Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 6/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.52 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585479 | 0.99 | PSMB1 (0.55) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL18824777 | 0.93 | HRH3 (0.56) | HRH3 | |
| SCHEMBL237631 | 0.92 | HRH3 (0.58) | HRH3 | |
| SCHEMBL18844624 | 0.90 | HRH3 (0.52) | HRH3ALDH1A1 | |
| SCHEMBL1367081 | 0.90 | LTA4H (0.52) | LTA4HKDM4EHRH3ALDH1A1 | |
| SCHEMBL171775 | 0.89 | ALDH1A1 (0.55) | LTA4HKDM4EPSMB1PSMB5HRH3 | |
| SCHEMBL29602879 | 0.89 | PSMB1 (0.43) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL25301027 | 0.88 | LTA4H (0.41) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL12435690 | 0.87 | LTA4H (0.41) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL22137694 | 0.87 | HRH3 (0.50) | LTA4HKDM4EPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| US-20240148722-A1 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4294811-A2 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022178338-A2 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | GELLIBERT FRANCOISE J | 2006-04-06 | — | — | US | disclosed |
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | DODIC NERINA | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | SMAD2, SMAD3, ALK | LTA4H 3056/4885KDM4E 514/4885PSMB1 3152/4885 |
| US-20240148722-A1 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | TARDBP, FUS, HSPE1 | LTA4H 3472/4885KDM4E 2340/4885PSMB1 740/4885 |
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMAD3, SMAD2, TGFBR1 | LTA4H 2753/4885KDM4E 1983/4885PSMB1 2895/4885 |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | LTA4H 3932/4885KDM4E 1474/4885PSMB1 1421/4885 |
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | LTA4H 592/4885KDM4E 3284/4885PSMB1 829/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | LTA4H 152/4885KDM4E 1494/4885PSMB1 2677/4885 |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | CDK6, ESR1, CDK4 | LTA4H 2094/4885KDM4E 543/4885PSMB1 1043/4885 |
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | SMAD3, TGFBR1, SMAD2 | LTA4H 2766/4885KDM4E 2260/4885PSMB1 2552/4885 |
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | LTA4H 2999/4885KDM4E 649/4885PSMB1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.